Ntx-470: mRNA drug candidate successfully engaged CD3 T cells

[Maxone73]

this sentence alone earned them the right to be mentioned “Nutcracker scientists were able to engineer multiple variants of LIGHT and NTX-470 to investigate the activities of each …”

ddw-online.com/mrna-prostat...

[GP24]

Biontech is also working on an mRNA therapy for prostate cancer:

In December 2023, the first patient was dosed in a Phase 1/2 clinical trial (NCT05682443) to evaluate the efficacy and safety of BNT316/ONC-392 in combination with the radioligand therapy, lutetium (177Lu) vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (“mCRPC”) who have progressed on an androgen receptor pathway inhibitor.

investors.biontech.de/news-...

[Maxone73 in reply to GP24]

Good!

[j-o-h-n in reply to Maxone73]

Me <---- shrugs shoulders, slaps forehead and moves on..... Thanks anyway...

Good Luck, Good Health and Good Humor.

j-o-h-n